Next Article in Journal
Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry
Next Article in Special Issue
The Influence of Comorbidities on Chemokine and Cytokine Profile in Obstructive Sleep Apnea Patients: Preliminary Results
Previous Article in Journal
From Virtual Reality to Regenerative Virtual Therapy: Some Insights from a Systematic Review Exploring Inner Body Perception in Anorexia and Bulimia Nervosa
Previous Article in Special Issue
Impact of a Weight-Loss Rehabilitation Program on Sleep Apnea Risk and Subjective Sleepiness in Patients with Overweight/Obesity: The DietSleep Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 23
10.3390/jcm11237135
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms

by
Agata Gabryelska
1,*,
Szymon Turkiewicz
1,
Marta Ditmer
1,
Filip Franciszek Karuga
1,
Dominik Strzelecki
2,
Piotr Białasiewicz
1 and
Marcin Sochal
1,*
1
Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 90-419 Lodz, Poland
2
Department of Affective and Psychotic Disorders, Medical University of Lodz, 90-419 Lodz, Poland
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(23), 7135; https://doi.org/10.3390/jcm11237135
Submission received: 10 November 2022 / Revised: 27 November 2022 / Accepted: 28 November 2022 / Published: 30 November 2022
(This article belongs to the Special Issue Obstructive Sleep Apnea with Cardiovascular, Metabolic and Mental Health Disorders)
Browse Figures
Versions Notes

Abstract

:
Introduction: Obstructive sleep apnea (OSA) is a disorder that, apart from somatic sequelae, increases the risk of developing psychiatric conditions. Brain-derived neurotrophic factor (BDNF) signaling pathway is involved in the pathophysiology of depression and insomnia. Therefore, the study aimed to investigate differences in concentrations of BDNF and proBDNF in patients with OSA and healthy individuals, to evaluate diurnal changes of these proteins, and to assess the correlations with psychiatric symptoms. Methods: Sixty individuals following polysomnography (PSG) were divided into two groups based on the apnea-hypopnea index (AHI): OSA patients (AHI ≥ 30; n = 30) and control group (AHI < 5; n = 30). Participants filled out questionnaires: Beck Depression Inventory (BDI), Athens Insomnia Scale (AIS), and Pittsburgh Sleep Quality Index (PSQI). Peripheral blood was collected before and after PSG. Protein concentrations were measured using ELISA. OSA group was divided into subgroups: AIS (−)/AIS (+) (AIS > 5), PSQI (−)/PSQI (+) (PSQI > 5), and BDI (−)/BDI (+) (BDI > 19). Results: No differences in BDNF and proBDNF protein levels were observed between OSA and the control groups. However, BDNF and proBDNF evening protein concentrations were higher in the AIS (+) and PSQI (+) groups (p < 0.001 for all). The BDI (+) group was characterized by lower morning levels of both proteins (p = 0.047 and p = 0.003, respectively). Conclusions: BDNF signaling pathway might be involved in the pathophysiology of depression and insomnia in patients with OSA. BDNF and proBDNF protein levels might be useful in defining OSA phenotypes.

1. Introduction

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by recurrent pauses in breathing during sleep due to partial or complete obstruction of the upper airways [1]. Numerous pauses in breathing conduce to intermittent hypoxia (IH), which is closely correlated with systemic inflammation and oxidative stress [2]. Those factors might contribute to OSA comorbidities, like hypertension, other cardiovascular diseases, or metabolic disorders, especially type II diabetes mellitus [3,4,5,6,7,8]. Studies have also highlighted the association between conditions with immune-mediated background and OSA, which indicates some immune system dysregulation occurring in the course of OSA in susceptible individuals [9,10,11,12,13].
Recently more studies have been focusing on the psychiatric aspects of this disorder, i.e., increased prevalence of affective diseases (particularly depression), cognitive impairment, or co-existing insomnia. The prevalence of this condition in patients with OSA in some studies reaches up to 84% [14]; it might greatly affect a patient’s prognosis and overall health as well as affect adherence to treatment and its potential effectiveness [15,16,17]. In one study, the risk of all-cause mortality in the OSA group with comorbid insomnia was 47% higher than non-insomnia OSA controls [18]. Regarding presence of depressive symptoms in patients with OSA, Jehan et al. reported that about 20% of patients with OSA might suffer from a major depressive disorder (MDD) [19]. In a large cohort study, MDD with concomitant OSA was associated with a higher prevalence of suicidal behaviors, defined as attempts or suicidal ideation [20].
Brain-derived neurotrophic factor (BDNF), a neurotrophin (NT) produced in the central nervous system, has the ability to cross the blood-brain barrier, thus, has been widely studied in psychiatric disorders [21,22,23,24]. BDNF regulates the development and functioning of several signal pathways, such as Ras/MAPK, PI3K/Akt, and PKC/PLC. Its premature form (proBDNF) has the opposite activity and leads to the activation of pro-apoptotic factors in neural cells [25]. This NT has already been correlated with numerous disturbances characteristic of OSA, such as neurocognitive decline [26], sleep disturbances [27], or depression [28,29].
There is limited data, with contradicting results regarding BDNF levels in patients with OSA [30,31,32,33]. To the best of our knowledge, no studies up to date have evaluated the concentration of this neurotrophin in the context of depressive and insomnia symptoms in patients with OSA. Therefore, the study aimed to investigate differences in concentration of BDNF and proBDNF in patients with OSA and healthy participants, to evaluate their diurnal changes, and to assess their correlations with insomnia and depression symptoms that might contribute to specific OSA phenotypes.

2. Materials and Methods

2.1. Sample

The study group included 60 participants referred to the Sleep and Respiratory Disorders Centre in Lodz (Poland) with potential OSA diagnosis. Each participant underwent a standard nocturnal polysomnography (PSG) examination. Based on the apnea-hypopnea index (AHI), patients were divided into the OSA group (n = 30; AHI ≥ 30) and the healthy control group (n = 30; AHI < 5). The exclusion criteria included inflammatory diseases (e.g., connective tissue diseases or inflammatory bowel diseases), chronic respiratory diseases (e.g., bronchial asthma or chronic obstructive pulmonary disease), any infection within one month of blood collection, diagnosis of cancer (in medical history), diagnosed major neurological conditions, diagnosed psychiatric disorders including insomnia and taking medications affecting sleep (e.g., benzodiazepines and melatonin). The study was approved by the Ethics Committee of the Medical University of Lodz (RNN/432/18/KE). All patients provided written informed consent to participate in the study.

2.2. Polysomnography

Patients were admitted to the sleep lab at 21:00 h (±0.5 h) and underwent physical examination (measurement of body mass, height, heart rate, and blood pressure). Standard nocturnal polysomnography was performed by recording the following channels: electroencephalography (C4\A1, C3\A2), chin muscles and anterior tibialis electromyography, electrooculography, measurements of oronasal airflow (a thermistor gauge), snoring, body position, respiratory movements of chest and abdomen (piezoelectric gauges), unipolar electrocardiogram and hemoglobin oxygen saturation (SpO2) (Alice 6, Phillips-Respironics). Sleep stages were scored according to the criteria based on the 30-s epoch standard [34]. Apnea was attained with over 90% the airflow reduction for at least 10 s. Hypopnea was defined as at least a 30% reduction of airflow for at least 10 s, accompanied by over a 3% decrease in SpO2 or arousal. Encephalography arousals were scored according to the American Academy of Sleep Medicine guidelines [34].

2.3. Questionnaires

Questionnaires included three research instruments: Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and Athens Insomnia Scale (AIS). They were filled in by each participant in the morning after polysomnography.

2.3.1. Pittsburgh Sleep Quality Index (PSQI)

Self-evaluation questionnaire assessing seven different aspects of sleep in adults. It evaluates sleep quality parameters such as difficulties with falling asleep, problems with maintaining continuity of sleep, functioning during the day, and questions regarding the most frequent causes of sleep disorders over the past four weeks. They all make up the outcome, assessed from 0 to 21 points. Results higher than 5 points indicate low sleep quality and differentiate patients into “poor” and “good” sleep [35,36,37]. This principle was used to determine the cutoff point used to divide patients with OSA into two groups: the PSQI (−) group (PSQI ≤ 5) and the PSQI (+) group (PSQI > 5). PSQI proved to have high internal consistency, as indicated by Cronbach’s alpha of 0.83 [38]. A validated PSQI version in Polish was used in the study [39].

2.3.2. Beck Depression Inventory (BDI)

The self–evaluation questionnaire consists of 21 questions, which assesses the intensification of each depression symptom on a 4-grade scale from 0 to 3 points. All answers are added up, giving a maximum score of 63 points. BDI is a quick and simple screening test. The BDI interpretation divides results into four groups: slight depression (0–13), mild depression (14–19), moderate depression (20–28), and severe depression (29–63) [40,41]. The questionnaire doesn’t define a lack of depression [42]. Its validity and reliability were determined by Cronbach’s alpha of 0.913 [43]. We used 19 points result as a cutoff point to determine OSA groups with poor and intensified symptoms of depression: the BDI (−) group (BDI ≤ 19) and BDI (+) group (BDI > 19), respectively. A validated BDI version in Polish was used in the study [44,45].

2.3.3. Athens Insomnia Scale (AIS)

A questionnaire consisting of 8 questions dedicated to insomnia studies. The first five questions are according to the ICD-10 criterion of insomnia diagnosis, including assessing difficulty with sleep induction, awakening, total sleep time, and overall quality of sleep. The last three items evaluate day consequences of insomnia, such as subsequent day well-being, functioning, and daytime sleepiness [46]. Each question is scored from 0 to 3 points, corresponding to “no problem at all” to “very serious problem”, respectively. Summarizing all items assessed to 24 points in total. Saldatos et al. reported that the cutoff score is 5.5 points in European countries [46], and it was used in the study to determine the AIS (−) group (AIS ≤ 5) and AIS (+) group (AIS > 5). A validated AIS version in Polish was used in the study [47].

2.4. Blood Collection and Protein Level Assessment

Peripheral blood samples were collected in the evening before and in the morning following PSG examination into collection tubes with a clot activator. Blood samples were centrifuged immediately following the blood draws at 4 °C. The serum was collected and stored at −80 °C. The serum BDNF and proBDNF protein concentrations were assessed by ELISA kit (Human BDNF (Brain-Derived Neurotrophic Factor) ELISA Kit and Human pro-BDNF (pro-Brain-Derived Neurotrophic Factor) ELISA Kit respectively, FineTest, Wuhan, China). The absorbance was measured at λ = 450 nm wavelength by an absorbance reader (BioTek 800 TS, Agilent Technologies, Santa Clara, CA, USA).

2.5. Statistical Analysis

Statistical analysis was performed at a significance level of 0.05 using two-tailed tests. The normality of the distribution of variables was tested with the Shapiro-Wilk test. For variables with a normal distribution, the data is presented as the mean with the standard deviation; for variables with a distribution other than normal, the data is presented as the median with the interquartile range (IQR). Chi-square and Chi-square tests with Yate’s correction were used to assess nominal variables in situations where the size of the smallest group was, respectively: above 15 and in the range of 5–15. Comparisons of independent groups were made using the student’s t-test (for variables with a normal distribution) and the Mann-Whitney U test (for variables with a different distribution than normal). Dependent groups were compared with the t-student test for dependent variables (for variables with a normal distribution) or Wilcoxon (for variables with a different distribution than normal). Correlations between continuous variables were tested with Spearman’s rank correlation test. The analysis was performed using IBM SPSS Statistics version 28 (2021, Armonk, NY, USA).

3. Results

Baseline characteristics and comparison between the control group (n = 30) and OSA group (n = 30), including demographic data, polysomnography parameters, protein concentrations, and questionnaire results, are shown in Table 1.
No differences were found between the morning and the evening protein concentrations in the case of BDNF (p = 0.162) and proBDNF (p = 0.791) in all participants of the study; similarly, no differences were observed in the control group (p = 0.232 and p = 0.439 respectively) and the OSA group (p = 0.624 and p = 0.821 respectively) (Figure 1).
In the OSA group, strong positive correlations between the morning and the evening of BDNF (r = 0.580, p < 0.001) and proBDNF (r = 0.527, p = 0.003) concentration were observed. Moreover, a very strong positive correlation between BDNF and proBDNF protein concentration in the morning (r = 0.860, p < 0.001) and in the evening (r = 0.923, p < 0.001), respectively, was achieved. Additionally, BDNF protein concentration positively correlated with total sleep time both in the evening (r = 0.386, p = 0.035) and in the morning (r = 0.412, p = 0.024) (Figure 2).
In further analysis, the OSA group was divided based on results on AIS (≤5 and >5), PSQI (≤5 and >5), and BDI (≤20 and >20), the comparisons between the subgroups and baseline characteristics are shown in Table 2. AIS (+) subjects had increased evening BDNF and proBDNF levels in contrast with its AIS (−) group (18.8 (6.1–26.7) vs. 6.6 (6.2–8.1) p < 0.001, and 9.7 (2.5–28.0) vs. 3.1 (2.1–3.8) p < 0.001 respectively, Figure 3A). Similar results of evening BDNF and proBDNF were also obtained between PSQI (+) and PSQI (−) groups (17.5 (6.0–26.4) vs. 6.6 (6.4–8.1) p < 0.001, and 8.6 (2.5–13.9) vs. 2.9 (2.0–4.0) p < 0.001 respectively, Figure 3B). Furthermore, decreased morning BDNF and proBDNF levels were observed in the BDI (+) group compared to the BDI (−) group (6.6 (5.2–14.3) vs. 16.2 (8.0–26.7) p = 0.047, and 3.5 (±1.7) vs. 7.8 (±5.1) p = 0.003 respectively, Figure 3C).
Furthermore, an increased level of the morning compared to the evening BDNF and proBDNF protein concentrations were achieved in the AIS (−) group (14.0 (8.0–17.8) vs. 6.6 (6.2–8.1) ng/mL p = 0.033 and 6.0 (3.6–9.2) vs. 3.1 (2.1–3.8) ng/mL p = 0.035 respectively, Figure 3A) and the PSQI (−) group 13.4 (6.9–17.3) vs. 6.6 (6.4–8.1) ng/mL p = 0.043 and 5.8 (2.7–8.6) vs. 2.9 (2.0–4.0) ng/mL p = 0.046 respectively, Figure 3B), while no differences in protein diurnal levels were observed in the AIS (+), the PSQI (+), the BDI (+) as well as BDI (−) groups (Figure 3).

4. Discussion

BDNF signaling pathway might be a contributor to the course of OSA. It seems to influence the risk of developing OSA comorbidities, such as insomnia, cognitive impairment, and depression. In this study, we demonstrated increased evening levels of BDNF and proBDNF in patients with OSA who scored high on questionnaires assessing poor sleep quality and insomnia symptoms (PSQI and AIS, respectively). Moreover, the severity of depression symptoms assessed with BDI was associated with decreased morning serum levels of both proteins in the OSA group. This may suggest the plausible involvement of those proteins in developing mood and sleep disorders in OSA. In addition, serum levels of BDNF and proBDNF are not significantly different between healthy individuals and patients with severe OSA, and no diurnal changes are present.
The majority of evidence indicates that intermittent hypoxia, one of the most damaging effects of OSA, causes decreases in BDNF levels in animal models [48,49,50,51,52,53,54]. Fang et al. studied the influence of CIH (chronic intermittent hypoxia) on neurodegeneration of the optic nerve in mice model, showing decreased BDNF levels. Those changes were reversible after 7,8-dihydroxyflavone (7,8-DHF) administration, an antioxidant [48]. After 7,8-DHF application, oxidative stress was reduced, and BDNF/TrkB/CREB pathway increased in activity, which emphasized the role of reactive oxygen species (ROS) in the impairment of BDNF expression [21,55]. Mice and piglet model of OSA confirmed the involvement of Trk/CREB pathway regulation of the BDNF disruption [51,56]. Another study obtained similar results of BDNF pathway downregulation in the CIH mice model, but it emphasized the role of impaired iron metabolism as a potential pathomechanism [49].
Our study didn’t find any significant differences in BDNF and proBDNF levels between OSA and the healthy control group. Interestingly, most human studies on BDNF in OSA showed no differences in BDNF levels [30,31,32,57,58,59]. On the other hand, Shah et al. showed increased BDNF expression in the soft palate muscles of snorers and patients with OSA [60]. A possible explanation of this paradox is a time of exposure to IH. In studies on animal models time of exposure was between 3 to 12 weeks. OSA is a chronic disease, and it has been affecting patients for many years. This time is sufficient to activate the adaptive mechanisms. It has been suggested that sensorimotor neuropathy may cause upper airway collapse in patients with OSA [61]. Shah et al. showed that neuromuscular injuries caused by vibrating are typical in those groups of patients [62]. The following denervation was correlated with increased BDNF expression in the local environment, the same with swallowing dysfunction. The authors concluded that it might be an adaptation to neuromuscular injuries, which can lead to reinnervation [60]. Flores et al. also observed increased BDNF levels in patients with OSA. They emphasized the role of BDNF in neuroprotection in patients with OSA. In their study, higher BDNF levels correlated with higher oxygen desaturation index and with the Montreal Cognitive Assessment questionnaire score; it suggests that an increase in BDNF concentration might result in an improvement in cognitive functions. Thus, BDNF could be considered as o protective factor against cognitive decline [33]. Arslan et al. also reported the protective role of BDNF in patients with OSA in response to neurodegeneration. In their study, they found increased levels in mild and moderate-to-sever OSA than in healthy participants [63]. Moreover, BDNF levels correlated positively with the hypoxia [63]. In the same study, a similar correlation was also received for hypoxia and neurofilament light chain level (NF-L) [63], which is used as a biomarker of axonal damage in the AD [64]. However, the correlation of BDNF with NF-L in each group was insignificant [63]. The impact of hypoxia-inducible factor 1 (HIF-1) is worth considering in the context of adaptation to IH. We’ve already shown that patients with OSA are characterized by overexpression of HIF-1 [65,66,67], with other groups reporting similar results [68]. HIF-1 is a factor that mediates hypoxia-dependent response. Among the numerous targets, BDNF is one of them [69], and potentially overexpression of HIF-1 may affect the BDNF signaling pathway in patients with OSA, but it needs further research.
One of the main findings of our study is that patients with OSA with poor sleep and insomnia have higher evening BDNF and proBDNF levels. Moreover, the level of both proteins was positively correlated with total sleep time (TST). Even though the effect sizes of these differences in our studies were low, they were in line with Kaminska et al. and More et al., who showed a similar association between daytime sleepiness and BDNF overexpression in OSA [32,70]. In these studies, daytime sleepiness was evaluated by ESS. Yet, the above outcomes contradict the recent results of insomnia studies, where objective sleep and subjective sleep were correlated with lower serum levels of BDNF [71,72,73]. Fan et al. pointed out that decreased BDNF levels characterized insomnia patients with SSD, lower than 6 h compared to insomnia patients with sleep duration ≥ 6 h and controls. Moreover, the SSD group showed impaired neurocognitive functions, which correlated positively with BDNF levels [71]. What is more, Mikoteit et al. investigated subjective insomnia using Insomnia Severity Index (ISI); the severity of symptoms was correlated with decreased BDNF levels. In contrast to Fan’s outcomes, Micoteit et al. showed a correlation between decreased BDNF levels and decreased REM sleep in objective insomnia patients, not with sleep duration [72]. Another study on individuals with insomnia also confirmed the relationship between the severity of subjective sleep impairment and lower serum BDNF levels [73]. Down-regulation of BDNF in insomnia could be explained by hyperactivity of the stress response system and inflammation. Hyperactivity of the hypothalamus-pituitary-adrenal glands axis (HPA) is caused by hyperarousal. In insomnia patients, morning cortisol level is increased [74], and nocturnal melatonin production is diminished [75], which can disturb sleep and its structure, for instance, by REM-sleep changes. Claro et al. emphasized the impact of the stress itself on inflammation and BDNF levels without binding them directly [76]. Thereupon, a positive correlation between proBDNF, BDNF, and total sleep time in OSA and a higher level of expression of studied proteins in OSA individuals with poor sleep quality and insomnia symptoms indicate that patients afflicted with this disease might develop specific compensational mechanisms which are associated with increased expression of studied neurotrophins. Another finding, namely a positive correlation between the level of BDNF and its precursor, which could suggest relatively high activity of the BDNF pathway, might partially corroborate this hypothesis. A possible adaptive mechanism of BDNF pathways upregulation in OSA was described above. This is in line with results form a study where groups did not differ regarding age and sex [33]. In conclusion, BDNF levels may be useful in defining the insomnia phenotype in patients with OSA characterized by excessive daytime sleepiness. It is necessary to understand the complexity of the relationship between sleep disturbances and BDNF. Further research on the exact mechanisms driving this association is warranted.
Circadian clock disruption is a feature property of OSA. Our recent studies confirmed decreased levels of circadian clock proteins, such as period 1 protein (PER1) and aryl hydrocarbon receptor nuclear translocator-like protein 1 (BMAL1), in patients with OSA [77,78]. BDNF protein’s expression and its mRNA show dependence on the circadian rhythm: mRNA and BDNF protein levels are elevated during biological night and day, respectively [79]. In this study, we found higher BDNF and proBDNF levels in the morning than in the evening only in the AIS (−) and the PSQI (−) groups. The lack of significant differences in the protein levels in the AIS (+) and the PSQI (+) groups may indicate a possible connection with impaired circadian rhythm.
OSA is well known for neurobehavioral and cognitive deficits, such as decreased attention and vigilance, phonological problems, irritability, and impairment in executive functions and the long-term memory [26]. Neurocognitive impairment was correlated with decreased BDNF levels in the hippocampus several times in mice models of OSA [49,53,79]. Its pathomechanism is complex; nevertheless, it is based on the IH. Oxidative stress caused by IH damages synapses and neurofilaments directly, including postsynaptic density protein 95 failure, impairs new synaptic connections’ development [49], and inhibits serotonergic signaling. Wall et al. found that mice had impaired hippocampal neuroplasticity after seven days of IH, measured by long-term potentiation (LTP) in the CA1 region but not in the dentate gyrus [80]. Similar outcomes were obtained by Xie et al. [53]. In the latter study’s proposed mechanism, IH and sleep fragmentation directly lead to decreased neuronal excitability, decreased BDNF expression, and enhanced generation of reactive oxygen species [26]. They all impact neurocognitive dysfunction by impairing synaptic plasticity and promoting neuronal apoptosis, which contributes to depression. This could be confirmed to some extent by decreased morning BDNF and proBDNF levels with a medium effect size in the OSA group, with BDI (+) scores observed in our study. It would mean that reduction of BDNF in patients with OSA with depression symptoms may further exacerbate symptoms of this disease and hinder the therapeutic effects of antidepressants.
The main limitation of the study was the small size of the groups. Moreover, insomnia and depression assessments were based on questionnaires, with no other clinical investigation. Additionally, the study design (cross-sectional) prevents a conclusion on the causality. Prospective, interventional trials are necessary to understand the nature of this relationship.

5. Conclusions

Results of the study suggest that BDNF and proBDNF may be associated with symptoms of insomnia and depression in patients with OSA. Higher BDNF levels may define OSA phenotypes with comorbid insomnia, provide a better description of this heterogenic disorder, and further support proper treatment decisions. Similarly, lower BDNF and proBDNF levels may define OSA phenotypes with intensified symptoms of depression. However, the lack of differences in those protein levels between OSA and control groups indicates the greater complexity of the relationship. Further research is needed to verify the role of BDNF and its precursor in the development of psychiatric OSA comorbidities and assess the effect of treatment on these proteins.

Author Contributions

Conceptualization, A.G. and M.S.; Methodology, A.G. and M.S.; Formal analysis, A.G.; Investigation, A.G., S.T., M.D. and M.S.; Writing—original draft, A.G., S.T. and M.D.; Writing—review & editing, A.G., S.T., M.D., F.F.K., D.S., P.B. and M.S.; Visualization, A.G.; Funding acquisition, A.G. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by the Ministry of Education and Science (Poland) grant no. SKN/SP/496681/2021.

Institutional Review Board Statement

The study was approved by the Ethics Committee of the Medical University of Lodz (RNN/432/18/KE). All patients provided written informed consent to participate in the study.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data will be made available upon request.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AbbreviationsFull Name
7:8-DHF7,8-dihydroxyflavone
AHIapnea-hypopnea index
AISAthens Insomnia Scale
AktAKT serine/threonine kinase
BDIBeck Depression Inventory
BDNFbrain-derived neurotrophic factor
BMAL1aryl hydrocarbon receptor nuclear translocator-like protein 1
CIH chronic intermittent hypoxia
CPAPcontinous positive airway pressure
CREBCREB binding protein
EDSexcessive daytime sleepiness
HIF-1hypoxia-inducable factor 1
HPAhypothalamus-pituitary-adrenal glands axis
IH intermittent hypoxia
IL1interleukin 1
IQRinterquartile range
JNKmitogen-activated protein kinase 8
LTPlong-term potentiation
MAPKmitogen-activated protein kinase 1
MDDmajor depressive disorder
NREMnon-rapid eye movement
NTneurotrophin
OSAobstructive sleep apnea
PER1period 1 protein
PI3K-4,5-bisphosphate 3-kinase catalytic subunit
PKCprotein kinase C
PLCphospholipase C
proBDNFpremature BDNF
PSGpolysomnography
PSQIPittsburgh Sleep Quality Index
RasKRAS proto-oncogene
REMrapid eye movement
ROSreactive oxygen species
SAPKmitogen-activated protein kinase 4
SpO2hemoglobin oxygen saturation
TrkBneurotrophic receptor tyrosine kinase 2

References

  1. Gottlieb, D.J.; Punjabi, N.M. Diagnosis and Management of Obstructive Sleep Apnea: A Review. JAMA 2020, 323, 1389–1400. [Google Scholar] [CrossRef] [PubMed]
  2. Hosseini, H.; Homayouni-Tabrizi, M.; Amiri, H.; Safari-Faramani, R.; Moradi, M.-T.; Fadaei, R.; Khazaie, H. The effect of continuous positive airway pressure on total antioxidant capacity in obstructive sleep apnea: A systematic review and meta-analysis. Sleep Breath. 2022. [Google Scholar] [CrossRef] [PubMed]
  3. Gabryelska, A.; Chrzanowski, J.; Sochal, M.; Kaczmarski, P.; Turkiewicz, S.; Ditmer, M.; Karuga, F.F.; Czupryniak, L.; Białasiewicz, P. Nocturnal Oxygen Saturation Parameters as Independent Risk Factors for Type 2 Diabetes Mellitus among Obstructive Sleep Apnea Patients. J. Clin. Med. 2021, 10, 3770. [Google Scholar] [CrossRef] [PubMed]
  4. Heinzer, R.; Vat, S.; Marques-Vidal, P.; Marti-Soler, H.; Andries, D.; Tobback, N.; Mooser, V.; Preisig, M.; Malhotra, A.; Waeber, G.; et al. Prevalence of sleep-disordered breathing in the general population: THE HypnoLaus study. Lancet Respir. Med. 2015, 3, 310–318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Tietjens, J.R.; Claman, D.; Kezirian, E.J.; De Marco, T.; Mirzayan, A.; Sadroonri, B.; Goldberg, A.N.; Long, C.; Gerstenfeld, E.P.; Yeghiazarians, Y. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy. J. Am. Heart Assoc. 2019, 8, e010440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Yeghiazarians, Y.; Jneid, H.; Tietjens, J.R.; Redline, S.; Brown, D.L.; El-Sherif, N.; Mehra, R.; Bozkurt, B.; Ndumele, C.E.; Somers, V.K. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021, 144, e56–e67. [Google Scholar] [CrossRef] [PubMed]
  7. Reutrakul, S.; Mokhlesi, B. Obstructive Sleep Apnea and Diabetes: A State of the Art Review. Chest 2017, 152, 1070–1086. [Google Scholar] [CrossRef]
  8. Mok, Y.; Tan, C.W.; Wong, H.S.; How, C.H.; Tan, K.L.A.; Hsu, P.P. Obstructive sleep apnoea and Type 2 diabetes mellitus: Are they connected? Singap. Med. J. 2017, 58, 179–183. [Google Scholar] [CrossRef] [Green Version]
  9. Ditmer, M.; Gabryelska, A.; Turkiewicz, S.; Białasiewicz, P.; Małecka-Wojciesko, E.; Sochal, M. Sleep Problems in Chronic Inflammatory Diseases: Prevalence, Treatment, and New Perspectives: A Narrative Review. J. Clin. Med. 2021, 11, 67. [Google Scholar] [CrossRef]
  10. Gabryelska, A.; Sochal, M.; Wasik, B.; Białasiewicz, P. Patients With Obstructive Sleep Apnea Are Over Four Times More Likely to Suffer From Psoriasis Than the General Population. J. Clin. Sleep Med. 2018, 14, 153. [Google Scholar] [CrossRef]
  11. Kuna, K.; Szewczyk, K.; Gabryelska, A.; Białasiewicz, P.; Ditmer, M.; Strzelecki, D.; Sochal, M. Potential Role of Sleep Deficiency in Inducing Immune Dysfunction. Biomedicines 2022, 10, 2159. [Google Scholar] [CrossRef] [PubMed]
  12. Kang, J.-H.; Lin, H.-C. Obstructive sleep apnea and the risk of autoimmune diseases: A longitudinal population-based study. Sleep Med. 2012, 13, 583–588. [Google Scholar] [CrossRef]
  13. Parish, J.M. Genetic and immunologic aspects of sleep and sleep disorders. Chest 2013, 143, 1489–1499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Verbraecken, J. More than sleepiness: Prevalence and relevance of nonclassical symptoms of obstructive sleep apnea. Curr. Opin. Pulm. Med. 2022, 28, 552–558. [Google Scholar] [CrossRef] [PubMed]
  15. Gabryelska, A.; Sochal, M.; Wasik, B.; Szczepanowski, P.; Białasiewicz, P. Factors Affecting Long-Term Compliance of CPAP Treatment—A Single Centre Experience. J. Clin. Med. 2021, 11, 139. [Google Scholar] [CrossRef]
  16. Luyster, F.S.; Buysse, D.J.; Strollo, P.J.J. Comorbid insomnia and obstructive sleep apnea: Challenges for clinical practice and research. J. Clin. sleep Med. 2010, 6, 196–204. [Google Scholar] [CrossRef] [Green Version]
  17. Cistulli, P.A.; Armitstead, J.; Pepin, J.-L.; Woehrle, H.; Nunez, C.M.; Benjafield, A.; Malhotra, A. Short-term CPAP adherence in obstructive sleep apnea: A big data analysis using real world data. Sleep Med. 2019, 59, 114–116. [Google Scholar] [CrossRef]
  18. Lechat, B.; Appleton, S.; Melaku, Y.A.; Hansen, K.; McEvoy, R.D.; Adams, R.; Catcheside, P.; Lack, L.; Eckert, D.J.; Sweetman, A. Comorbid insomnia and sleep apnoea is associated with all-cause mortality. Eur. Respir. J. 2022, 60, 2101958. [Google Scholar] [CrossRef]
  19. Jehan, S.; Auguste, E.; Pandi-Perumal, S.R.; Kalinowski, J.; Myers, A.K.; Zizi, F.; Rajanna, M.G.; Jean-Louis, G.; McFarlane, S.I. Depression, Obstructive Sleep Apnea and Psychosocial Health. Sleep Med. Disord. Int. J. 2017, 1, 00012. [Google Scholar]
  20. Reddy, A.; Mansuri, Z.; Vadukapuram, R.; Trivedi, C. Increased Suicidality and Worse Outcomes in MDD Patients With OSA: A Nationwide Inpatient Analysis of 11 Years From 2006 to 2017. J. Acad. Consult. Psychiatry 2022, 63, 46–52. [Google Scholar] [CrossRef]
  21. Sochal, M.; Ditmer, M.; Gabryelska, A.; Białasiewicz, P. The Role of Brain-Derived Neurotrophic Factor in Immune-Related Diseases: A Narrative Review. J. Clin. Med. 2022, 11, 6023. [Google Scholar] [CrossRef] [PubMed]
  22. Shi, X.-J.; Du, Y.; Lei-Chen; Li, X.-S.; Yao, C.-Q.; Cheng, Y. Effects of brain-derived neurotrophic factor (BDNF) on the Schizophrenia model of animals. J. Psychiatr. Res. 2022, 156, 538–546. [Google Scholar] [CrossRef] [PubMed]
  23. Meshkat, S.; Alnefeesi, Y.; Jawad, M.Y.; Di Vincenzo, J.D.; Rodrigues, N.B.; Ceban, F.; Lui, L.M.; McIntyre, R.S.; Rosenblat, J.D. Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis. Psychiatry Res. 2022, 317, 114857. [Google Scholar] [CrossRef] [PubMed]
  24. Miuli, A.; Mancusi, G.; Pettorruso, M.; Di Carlo, F.; Clemente, K.; Di Meo, I.; D’Andrea, A.; Pernaci, G.; Di Crosta, T.; d’Andrea, G.; et al. Impact of sleep disorders and disease duration on neurotrophins levels in cocaine use disorder. Neurosci. Lett. 2022, 786, 136805. [Google Scholar] [CrossRef]
  25. Nordvall, G.; Forsell, P.; Sandin, J. Neurotrophin-targeted therapeutics: A gateway to cognition and more? Drug Discov. Today 2022, 27, 103318. [Google Scholar] [CrossRef]
  26. Xie, H.; Yung, W. Chronic intermittent hypoxia-induced deficits in synaptic plasticity and neurocognitive functions: A role for brain-derived neurotrophic factor. Acta Pharmacol. Sin. 2012, 33, 5–10. [Google Scholar] [CrossRef] [Green Version]
  27. Watson, A.J.; Henson, K.; Dorsey, S.G.; Frank, M.G. The truncated TrkB receptor influences mammalian sleep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2015, 308, R199–R207. [Google Scholar] [CrossRef] [Green Version]
  28. Castrén, E.; Monteggia, L.M. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biol. Psychiatry 2021, 90, 128–136. [Google Scholar] [CrossRef]
  29. Sochal, M.; Małecka-Panas, E.; Gabryelska, A.; Fichna, J.; Talar-Wojnarowska, R.; Szmyd, B.; Białasiewicz, P. Brain-derived neurotrophic factor is elevated in the blood serum of Crohn’s disease patients, but is not influenced by anti-TNF-α treatment—A pilot study. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 2021, 33, e13978. [Google Scholar] [CrossRef]
  30. Panaree, B.; Chantana, M.; Wasana, S.; Chairat, N. Effects of obstructive sleep apnea on serum brain-derived neurotrophic factor protein, cortisol, and lipid levels. Sleep Breath. 2011, 15, 649–656. [Google Scholar] [CrossRef]
  31. Campos-Rodriguez, F.; Asensio-Cruz, M.I.; Cordero-Guevara, J.; Jurado-Gamez, B.; Carmona-Bernal, C.; Gonzalez-Martinez, M.; Troncoso, M.F.; Sanchez-Lopez, V.; Arellano-Orden, E.; Garcia-Sanchez, M.I.; et al. Effect of continuous positive airway pressure on inflammatory, antioxidant, and depression biomarkers in women with obstructive sleep apnea: A randomized controlled trial. Sleep 2019, 42, zsz145. [Google Scholar] [CrossRef] [PubMed]
  32. Kaminska, M.; O’Sullivan, M.; Mery, V.P.; Lafontaine, A.L.; Robinson, A.; Gros, P.; Martin, J.G.; Benedetti, A.; Kimoff, R.J. Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson’s disease (PD). Sleep Med. 2022, 90, 258–261. [Google Scholar] [CrossRef] [PubMed]
  33. Flores, K.R.; Viccaro, F.; Aquilini, M.; Scarpino, S.; Ronchetti, F.; Mancini, R.; Di Napoli, A.; Scozzi, D.; Ricci, A. Protective role of brain derived neurotrophic factor (BDNF) in obstructive sleep apnea syndrome (OSAS) patients. PLoS ONE 2020, 15, e0227834. [Google Scholar] [CrossRef] [Green Version]
  34. Kapur, V.K.; Auckley, D.H.; Chowdhuri, S.; Kuhlmann, D.C.; Mehra, R.; Ramar, K.; Harrod, C.G. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American academy of sleep medicine clinical practice guideline. J. Clin. Sleep Med. 2017, 13, 479–504. [Google Scholar] [CrossRef] [PubMed]
  35. Smyka, M.; Kosińska-Kaczyńska, K.; Sochacki-Wójcicka, N.; Zgliczyńska, M.; Wielgoś, M. Sleep quality according to the Pittsburgh Sleep Quality Index in over 7000 pregnant women in Poland. Sleep Biol. Rhythm. 2021, 19, 353–360. [Google Scholar] [CrossRef]
  36. Backhaus, J.; Junghanns, K.; Broocks, A.; Riemann, D.; Hohagen, F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J. Psychosom. Res. 2002, 53, 737–740. [Google Scholar] [CrossRef] [PubMed]
  37. Chabowski, M.; Łuczak, J.; Dudek, K.; Jankowska-Polańska, B. Sleep disorders and adherence to inhalation therapy in patients with chronic obstructive pulmonary disease. Adv. Exp. Med. Biol. 2019, 1160, 43–52. [Google Scholar] [CrossRef]
  38. Mollayeva, T.; Thurairajah, P.; Burton, K.; Mollayeva, S.; Shapiro, C.M.; Colantonio, A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. Sleep Med. Rev. 2016, 25, 52–73. [Google Scholar] [CrossRef]
  39. Staniszewska, A.; Mąka, A.; Religioni, U.; Olejniczak, D. Sleep disturbances among patients with epilepsy. Neuropsychiatr. Dis. Treat. 2017, 13, 1797–1803. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Smarr, K.L.; Keefer, A.L. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionn. Arthritis Care Res. 2011, 63 (Suppl. S1), S454–S466. [Google Scholar] [CrossRef]
  41. Mirghafourvand, M.; Charandabi, S.M.A.; lak, T.B.; Aliasghari, F. Predictors of Depression in Iranian Women with Polycystic Ovarian Syndrome. Community Ment. Health J. 2018, 54, 1274–1283. [Google Scholar] [CrossRef] [PubMed]
  42. Beck, A.T.; Steer, R.A.; Brown, G. Beck depression inventory–II. Psychol. Assess. 1996. Available online: http://www.nctsn.org/content/beck-depression-inventory-second-edition-bdi-ii (accessed on 12 September 2022).
  43. Dabson, K.S.; MOHAMMAD, K.P. Psychometric characteristics of Beck depression inventory–II in patients with major depressive disorder. Brain Behav. 2007, 11, e2344. [Google Scholar] [CrossRef]
  44. Wiglusz, M.S.; Landowski, J.; Michalak, L.; Cubała, W.J. Validation of the Polish version of the Beck Depression Inventory in patients with epilepsy. Epilepsy Behav. 2017, 77, 58–61. [Google Scholar] [CrossRef] [PubMed]
  45. Kokoszka, A.; Cichoń, E.; Obrębski, M.; Kiejna, A.; Rajba, B. Cut-off points for Polish-language versions of depression screening tools among patients with Type 2 diabetes. Prim. Care Diabetes 2020, 14, 663–671. [Google Scholar] [CrossRef]
  46. Soldatos, C.R.; Dikeos, D.G.; Paparrigopoulos, T.J. Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria. J. Psychosom. Res. 2000, 48, 555–560. [Google Scholar] [CrossRef]
  47. Fornal-Pawłowska, M.; Wołyńczyk-Gmaj, D.; Szelenberger, W. Validation of the Polish version of the Athens Insomnia Scale. Psychiatr. Pol. 2011, 45, 211–221. [Google Scholar]
  48. Fang, Y.-Y.; Luo, M.; Yue, S.; Han, Y.; Zhang, H.-J.; Zhou, Y.-H.; Liu, K.; Liu, H.-G. 7,8-Dihydroxyflavone protects retinal ganglion cells against chronic intermittent hypoxia-induced oxidative stress damage via activation of the BDNF/TrkB signaling pathway. Sleep Breath. 2022, 26, 287–295. [Google Scholar] [CrossRef]
  49. An, J.R.; Zhao, Y.S.; Luo, L.F.; Guan, P.; Tan, M.; Ji, E.S. Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia. Life Sci. 2020, 250, 117573. [Google Scholar] [CrossRef] [PubMed]
  50. Yang, L.; Zhao, J.; Qu, Y.; Sun, Q.; Li, T.-T.; Yan, M.-L.; Duan, M.-J.; Li, K.-X.; Wang, Y.-R.; Huang, S.-Y.; et al. Metoprolol prevents neuronal dendrite remodeling in a canine model of chronic obstructive sleep apnea. Acta Pharmacol. Sin. 2020, 41, 620–628. [Google Scholar] [CrossRef]
  51. Wu, X.; Lu, H.; Hu, L.; Gong, W.; Wang, J.; Fu, C.; Liu, Z.; Li, S. Chronic intermittent hypoxia affects endogenous serotonergic inputs and expression of synaptic proteins in rat hypoglossal nucleus. Am. J. Transl. Res. 2017, 9, 546–557. [Google Scholar] [PubMed]
  52. Zhang, J.; Guo, X.; Shi, Y.; Ma, J.; Wang, G. Intermittent hypoxia with or without hypercapnia is associated with tumorigenesis by decreasing the expression of brain derived neurotrophic factor and miR-34a in rats. Chin. Med. J. 2014, 127, 43–47. [Google Scholar] [PubMed]
  53. Xie, H.; Leung, K.-L.; Chen, L.; Chan, Y.-S.; Ng, P.-C.; Fok, T.-F.; Wing, Y.-K.; Ke, Y.; Li, A.M.; Yung, W.-H. Brain-derived neurotrophic factor rescues and prevents chronic intermittent hypoxia-induced impairment of hippocampal long-term synaptic plasticity. Neurobiol. Dis. 2010, 40, 155–162. [Google Scholar] [CrossRef] [PubMed]
  54. Zhang, C.Q.; Yi, S.; Chen, B.B.; Cui, P.P.; Wang, Y.; Li, Y.Z. mTOR/NF-κB signaling pathway protects hippocampal neurons from injury induced by intermittent hypoxia in rats. Int. J. Neurosci. 2021, 131, 994–1003. [Google Scholar] [CrossRef] [PubMed]
  55. Turkiewicz, S.; Ditmer, M.; Sochal, M.; Białasiewicz, P.; Strzelecki, D.; Gabryelska, A. Obstructive Sleep Apnea as an Acceleration Trigger of Cellular Senescence Processes through Telomere Shortening. Int. J. Mol. Sci. 2021, 22, 12536. [Google Scholar] [CrossRef] [PubMed]
  56. Tang, S.; Machaalani, R.; Waters, K.A. Brain-derived neurotrophic factor (BDNF) and TrkB in the piglet brainstem after post-natal nicotine and intermittent hypercapnic hypoxia. Brain Res. 2008, 1232, 195–205. [Google Scholar] [CrossRef]
  57. Makhout, S.; Vermeiren, E.; Van De Maele, K.; Bruyndonckx, L.; De Winter, B.Y.; Van Hoorenbeeck, K.; Verhulst, S.L.; Van Eyck, A. The Role of Brain-Derived Neurotrophic Factor in Obstructive Sleep Apnea and Endothelial Function in a Pediatric Population With Obesity. Front. Med. 2022, 8, 835515. [Google Scholar] [CrossRef]
  58. Campos-Rodriguez, F.; Cordero-Guevara, J.; Asensio-Cruz, M.I.; Sanchez-Armengol, A.; Sanchez-Lopez, V.; Arellano-Orden, E.; Gozal, D.; Martinez-Garcia, M.A. Interleukin 6 as a marker of depression in women with sleep apnea. J. Sleep Res. 2021, 30, e13035. [Google Scholar] [CrossRef]
  59. Gabryelska, A.; Sochal, M. Evaluation of HIF-1 Involvement in the BDNF and ProBDNF Signaling Pathways among Obstructive Sleep Apnea Patients. Int. J. Mol. Sci. 2022, 23, 14876. [Google Scholar] [CrossRef]
  60. Shah, F.; Forsgren, S.; Holmlund, T.; Levring Jäghagen, E.; Berggren, D.; Franklin, K.A.; Stål, P. Neurotrophic factor BDNF is upregulated in soft palate muscles of snorers and sleep apnea patients. Laryngoscope Investig. Otolaryngol. 2019, 4, 174–180. [Google Scholar] [CrossRef] [Green Version]
  61. Svanborg, E. Upper airway nerve lesions in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2001, 164, 187–189. [Google Scholar] [CrossRef] [PubMed]
  62. Shah, F.; Holmlund, T.; Jäghagen, E.L.; Berggren, D.; Franklin, K.; Forsgren, S.; Stål, P. Axon and Schwann Cell Degeneration in Nerves of Upper Airway Relates to Pharyngeal Dysfunction in Snorers and Patients With Sleep Apnea. Chest 2018, 154, 1091–1098. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Arslan, B.; Şemsi, R.; İriz, A.; Dinçel, A.S. The evaluation of serum brain-derived neurotrophic factor and neurofilament light chain levels in patients with obstructive sleep apnea syndrome. Laryngoscope Investig. Otolaryngol. 2021, 6, 1466–1473. [Google Scholar] [CrossRef] [PubMed]
  64. Targa, A.; Dakterzada, F.; Benítez, I.; López, R.; Pujol, M.; Dalmases, M.; Arias, A.; Sánchez-de-la-Torre, M.; Zetterberg, H.; Blennow, K.; et al. Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer’s disease. Sleep 2021, 44, zsaa147. [Google Scholar] [CrossRef] [PubMed]
  65. Gabryelska, A.; Szmyd, B.; Panek, M.; Szemraj, J.; Kuna, P.; Białasiewicz, P. Serum hypoxia-inducible factor-1α protein level as a diagnostic marker of obstructive sleep apnea. Pol. Arch. Intern. Med. 2020, 130, 158–160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Gabryelska, A.; Szmyd, B.; Szemraj, J.; Stawski, R.; Sochal, M.; Białasiewicz, P. Patients with obstructive sleep apnea present with chronic upregulation of serum HIF-1α protein. J. Clin. sleep Med. 2020, 16, 1761–1768. [Google Scholar] [CrossRef]
  67. Gabryelska, A.; Stawski, R.; Sochal, M. Influence of one-night CPAP therapy on the changes of HIF-1α protein in OSA patients—A pilot study. J. Sleep Res. 2020, 29, e12995. [Google Scholar] [CrossRef]
  68. Lu, D.; Li, N.; Yao, X.; Zhou, L. Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome. Bosn. J. basic Med. Sci. 2017, 17, 47–53. [Google Scholar] [CrossRef] [Green Version]
  69. Qaid, E.Y.A.; Zulkipli, N.N.; Zakaria, R.; Ahmad, A.H.; Othman, Z.; Muthuraju, S.; Sasongko, T.H. The role of mTOR signalling pathway in hypoxia-induced cognitive impairment. Int. J. Neurosci. 2021, 131, 482–488. [Google Scholar] [CrossRef]
  70. More, C.E.; Papp, C.; Harsanyi, S.; Gesztelyi, R.; Mikaczo, A.; Tajti, G.; Kardos, L.; Seres, I.; Lorincz, H.; Csapo, K.; et al. Altered irisin/BDNF axis parallels excessive daytime sleepiness in obstructive sleep apnea patients. Respir. Res. 2019, 20, 67. [Google Scholar] [CrossRef] [Green Version]
  71. Fan, T.-T.; Chen, W.-H.; Shi, L.; Lin, X.; Tabarak, S.; Chen, S.-J.; Que, J.-Y.; Bao, Y.-P.; Tang, X.-D.; Shi, J.; et al. Objective sleep duration is associated with cognitive deficits in primary insomnia: BDNF may play a role. Sleep 2019, 42, zsy192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Mikoteit, T.; Brand, S.; Eckert, A.; Holsboer-Trachsler, E.; Beck, J. Brain-derived neurotrophic factor is a biomarker for subjective insomnia but not objectively assessable poor sleep continuity. J. Psychiatr. Res. 2019, 110, 103–109. [Google Scholar] [CrossRef] [PubMed]
  73. Giese, M.; Unternährer, E.; Hüttig, H.; Beck, J.; Brand, S.; Calabrese, P.; Holsboer-Trachsler, E.; Eckert, A. BDNF: An indicator of insomnia? Mol. Psychiatry 2014, 19, 151–152. [Google Scholar] [CrossRef] [PubMed]
  74. Backhaus, J.; Junghanns, K.; Hohagen, F. Sleep disturbances are correlated with decreased morning awakening salivary cortisol. Psychoneuroendocrinology 2004, 29, 1184–1191. [Google Scholar] [CrossRef]
  75. Riemann, D.; Klein, T.; Rodenbeck, A.; Feige, B.; Horny, A.; Hummel, R.; Weske, G.; Al-Shajlawi, A.; Voderholzer, U. Nocturnal cortisol and melatonin secretion in primary insomnia. Psychiatry Res. 2002, 113, 17–27. [Google Scholar] [CrossRef]
  76. Claro, A.E.; Palanza, C.; Mazza, M.; Rizzi, A.; Tartaglione, L.; Marano, G.; Muti-Schuenemann, G.; Rigoni, M.; Muti, P.; Pontecorvi, A.; et al. Why do we not reverse the path? Stress can cause depression, reduction of brain-derived neurotrophic factor and increased inflammation. World J. Psychiatry 2022, 12, 1264–1267. [Google Scholar] [CrossRef]
  77. Gabryelska, A.; Turkiewicz, S.; Karuga, F.F.; Sochal, M.; Strzelecki, D.; Białasiewicz, P. Disruption of Circadian Rhythm Genes in Obstructive Sleep Apnea Patients—Possible Mechanisms Involved and Clinical Implication. Int. J. Mol. Sci. 2022, 23, 709. [Google Scholar] [CrossRef]
  78. Gabryelska, A.; Sochal, M.; Turkiewicz, S.; Białasiewicz, P. Relationship between HIF-1 and Circadian Clock Proteins in Obstructive Sleep Apnea Patients—Preliminary Study. J. Clin. Med. 2020, 9, 1599. [Google Scholar] [CrossRef]
  79. Cain, S.W.; Chang, A.-M.; Vlasac, I.; Tare, A.; Anderson, C.; Czeisler, C.A.; Saxena, R. Circadian Rhythms in Plasma Brain-derived Neurotrophic Factor Differ in Men and Women. J. Biol. Rhythm. 2017, 32, 75–82. [Google Scholar] [CrossRef]
  80. Wall, A.M.; Corcoran, A.E.; O’Halloran, K.D.; O’Connor, J.J. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus. Neurobiol. Dis. 2014, 62, 8–17. [Google Scholar] [CrossRef]
Jcm 11 07135 g001 550
Figure 1. Comparison of diurnal protein levels. BDNF—brain-derived neurotrophic factor; OSA—obstructive sleep apnea proBDNF—premature brain-derived neurotrophic factor.
Figure 1. Comparison of diurnal protein levels. BDNF—brain-derived neurotrophic factor; OSA—obstructive sleep apnea proBDNF—premature brain-derived neurotrophic factor.
Jcm 11 07135 g001
Jcm 11 07135 g002 550
Figure 2. Correlations between BDNF and proBDNF protein levels and chosen parameters BDNF—brain-derived neurotrophic factor; proBDNF—premature brain-derived neurotrophic factor; TST—total sleep time. (A)—Correlation between BDNF protein level in the morning and BDNF protein level in the evening. (B)—Correlation between proBDNF protein level in the morning and proBDNF protein level in the evening. (C)—Correlation between proBDNF protein level in the morning and BDNF protein level in the morning. (D)—Correlation between proBDNF protein level in the evening and BDNF protein level in the evening. (E)—Correlation between total sleep time and BDNF protein level in the evening. (F)—Correlation between total sleep time and BDNF protein level in the morning.
Figure 2. Correlations between BDNF and proBDNF protein levels and chosen parameters BDNF—brain-derived neurotrophic factor; proBDNF—premature brain-derived neurotrophic factor; TST—total sleep time. (A)—Correlation between BDNF protein level in the morning and BDNF protein level in the evening. (B)—Correlation between proBDNF protein level in the morning and proBDNF protein level in the evening. (C)—Correlation between proBDNF protein level in the morning and BDNF protein level in the morning. (D)—Correlation between proBDNF protein level in the evening and BDNF protein level in the evening. (E)—Correlation between total sleep time and BDNF protein level in the evening. (F)—Correlation between total sleep time and BDNF protein level in the morning.
Jcm 11 07135 g002
Jcm 11 07135 g003 550
Figure 3. Diurnal and between groups comparisons of BDNF and proBDNF protein levels. AIS—Athens Insomnia Scale; BDI—Beck Depression Inventory; BDNF—brain-derived neurotrophic factor; proBDNF—premature brain-derived neurotrophic factor; PSQI—Pittsburgh Sleep Quality Index; **—p < 0.001; *—p < 0.05. (A)—comparison of BDNF and proBDNF protein levels between participans with low AIS (−) and high AIS (+) scores. (B)—comparison of BDNF and proBDNF protein levels between participans with low PSQI (−) and high PSQI (+) scores. (C)—comparison of BDNF and proBDNF protein levels between participans with low BDI (−) and high BDI (+) scores.
Figure 3. Diurnal and between groups comparisons of BDNF and proBDNF protein levels. AIS—Athens Insomnia Scale; BDI—Beck Depression Inventory; BDNF—brain-derived neurotrophic factor; proBDNF—premature brain-derived neurotrophic factor; PSQI—Pittsburgh Sleep Quality Index; **—p < 0.001; *—p < 0.05. (A)—comparison of BDNF and proBDNF protein levels between participans with low AIS (−) and high AIS (+) scores. (B)—comparison of BDNF and proBDNF protein levels between participans with low PSQI (−) and high PSQI (+) scores. (C)—comparison of BDNF and proBDNF protein levels between participans with low BDI (−) and high BDI (+) scores.
Jcm 11 07135 g003
Table
Table 1. Baseline characteristics of the study groups.
Table 1. Baseline characteristics of the study groups.
Control Group (n = 30)OSA Group (n = 30)p-Value
Demographic dataSex [M (%)/F(%)]17 (56.7%)/13(43.3%)27 (90%)/3(10%)0.007
Age [years]46.5 (36.8–58.5)59.5 (48.8–67.0)<0.001
BMI [kg/m2]27.6 (24.3–30.7)36.0 (31.2–39.4)<0.001
PolysomnographyTST (h)6.0 ± 0.95.9 ± 1.10.994
REM (h)1.2 ± 0.51.2 ± 0.60.408
NREM (h)4.8 ± 0.74.7 ± 0.90.525
Sleep Efficiency (%)85.2 (76.4–91.1)83.8 (70.3–87.8)0.412
Sleep onset latency (min)19.5 (8.1–31.8)15.8 (7.4–29.4)0.647
Sleep Maintenance Efficiency (%)93.5 (82.6–97.4)89.1 (77.2–92.2)0.205
REM latency (min)102.5 (80.1–144.0)97.3 (56.4–164.3)0.595
Arousal index (events/h)9.4 (6.0–14.2)24.8 (18.3–34.5)<0.001
AHI (events/h)2.5 (1.3–4.2)49.0 (37.5–71.3)<0.001
AHI in REM sleep (events/h)4.0 ± 5.248.4 ± 25.9<0.001
AHI in NREM sleep (events/h)1.6 (1.1–3.7)47.6 (36.9–69.0)<0.001
Total nuber of desaturations10.5 (6.3–18.5)248.0 (203.0–383.5)<0.001
Desaturation Index2.5 ± 1.856.6 ± 26.3<0.001
Mean SpO2 of desaturations during sleep91.0 (90.0–92.4)86.0 (81.9–88.5)<0.001
QuestionnairesAIS10.0 (7.0–14.0)11.0 (7.5–13.5)0.902
PSQI10.0 (7.0–11.0)11.0 (7.0–13.0)0.378
Subjective sleep quality (component 1 PSQI)2.0 (1.0–2.0)2.0 (1.0–2.0)0.482
Sleep latency
(component 2 PSQI)		1.0 (1.0–2.0)1.0 (1.0–2.0)0.821
Sleep duration
(component 3 PSQI)		1.0 (0.0–2.0)2.0 (1.0–2.5)0.200
Sleep efficiency
(component 4 PSQI)		1.0 (0.0–2.0)1.0 (0.0–3.0)0.594
Sleep disturbance
(component 5 PSQI)		1.0 (1.0–2.0)2.0 (1.0–2.0)0.029
Use of sleep medication (component 6 PSQI)
[yes (%)/no (%)]		24(80%)/6(20%)22(73.3%)/8(27.7%)0.542
Daytime dysfunction
(component 7 PSQI)		2.0 (1.0–3.0)1.0 (1.0–2.5)0.452
Reported time spent lying in bed in PSQI (min)420.0 (390.0–540.0)450.0 (360.0–525.0)0.521
Subjective Sleep Efficiency in PSQI (%)79.9 ± 15.376.6 ± 15.40.403
BDI14.0 (7.0–20.0)11.0 (8.0–16.5)0.885
Protein ConcentrationBDNF evening [ng/mL]13.4 (6.8–22.8)9.0 (6.1–25.2)0.442
BDNF morning [ng/mL]19.7 (7.7–24.7)9.2 (6.6–23.4)0.626
proBDNF evening [ng/mL]6.1 (3.5–10.1)4.7 (2.5–11.8)0.559
proBDNF morning [ng/mL]7.7 (3.2–11.2)5.9 (3.0–11.1)0.496
AHI—apnea-hypopnea index; AIS—Athens Insomnia Scale; BDI—Beck Depression Inventory; BDNF—brain-derived neurotrophic factor; BMI—body mass index; NREM—non rapid eye movement sleep; OSA—obstructive sleep apnea, proBDNF—premature brain-derived neurotrophic factor; PSQI—Pittsburgh Sleep Quality Index; REM—rapid eye movement sleep; SpO2—oxygen saturation; TST—total sleep time.
Table
Table 2. Baseline characteristics of the study subgroups.
Table 2. Baseline characteristics of the study subgroups.
OSA Group (n = 30)OSA Group (n = 30)OSA Group (n = 30)
AIS (−) Group
(≤5; n = 6)		AIS (+) Group
(>5; n = 24)		p-ValuePSQI (−) Group
(≤5; n = 5)		PSQI (+) Group
(>5; n = 25)		p-ValueBDI (−) Group
(≤19; n = 25)		BDI (+) Group
(>19; n = 5)		p-Value
Demographic dataSex [M (%)/F(%)]6 (100%)/0 (0.0%)21 (87.5%)/3(12.5%)0.3615 (100%)/0(0.0%)22 (88.0%)/3 (12.0%)0.41424 92.0%)/1(8.0%)2(40.0%)/3(60.0%)0.064
Age [years]57.7 ± 10.157.5± 10.20.97956.4 ± 10.757.8 ± 10.10.78056.7 ±10.061.8 ± 9.80.307
BMI [kg/m2]35.5 ± 4.535.6 ± 5.70.96836.1 ± 4.835.5 ± 5.60.83535.2 ± 5.637.5 ± 3.80.399
PolysomnographyTST (h)6.1 ± 0.95.8 ± 1.20.5756.4 ± 0.85.8 ± 1.20.2845.9 ± 1.15.7 ± 1.10.701
REM (h)1.2 ± 0.71.2 ± 0.60.7631.4 ± 0.71.1 ± 0.60.3992.8 ± 1.61.5 ± 1.00.205
NREM (h)4.9 ± 0.64.7 ±0.90.6135.0 ± 0.64.7 ± 0.90.4394.8 ± 0.94.2 ± 0.70.170
Sleep Efficiency (%)80.3 ± 15.379.2 ± 14.20.89487.2 ± 8.111.8 ± 11.70.30580.0 ± 15.177.9 ± 11.30.808
Sleep onset latency (min)13.0
(5.5–27.4)		16.8
(8.1–30.1)		0.67911.1 ± 5.923.9 ± 24.50.02915.5
(7.3–25.3)		30.5
(9.8–78.5)		0.033
Sleep Maintenance Efficiency (%)88.7
(74.1–94.9)		89.1
(76.7–92.2)		0.80891.1 ± 5.123.9 ± 24.70.11589.1
(77.2–93.7)		88.0
(73.1–92.4)		0.992
REM latency (min)86.8 ± 33.0120.2 ± 70.220.10781.5 ± 33.868.7 ± 119.90.085117.0 ± 69.196.0 ± 44.10.521
arousal index (events/h)25.9
(23.0–28.2)		23.6
(16.6–36.5)		0.71024.7 ± 1.929.2 ± 18.20.23529.2 ± 17.324.6 ± 13.90.573
AHI48.3
(37.1–64.0)		49.7
(37.7–73.2)		0.60946.3
(36.6–63.3)		51.5
(38.1–72.2)		0.51953.0 ± 19.667.0 ± 34.90.213
AHI in REM sleep (events/h)42.7
(30.8–65.8)		47.4
(27.2–65.4)		0.63639.5
(22.5–56.2)		50.9
(27.2–65.9)		0.40745.2 ± 22.964.3 ± 36.50.134
AHI in NREM sleep (events/h)46.2
(33.0–64.2)		47.6
(37.9–70.6)		0.55737.3
(32.7–67.4)		47.6
(38.0–69.8)		0.47152.0 ± 20.567.8 ± 35.80.177
Total number of desaturations320.0
(249.5–498.5)		211.0
(188.5–383.5)		0.707347.0
(235.0–377.0)		229.5
(194.8–381.3)		0.605235.0
(188.5–363.0)		318.0
(215.8–727.0)		0.254
Desaturation Index53.3 ± 15.557.5 ± 28.50.73051.7 ± 16.857.6 ± 27.90.65354.8 ± 25.165.9 ± 33.10.398
Mean SpO2 of desaturations during sleep85.4
(84.4–86.9)		86.7
(81.2–88.8)		0.37685.1
(83.9–87.8)		86.4
(81.3–88.7)		0.42286.0
(82.5–88.2)		85.4
(81.6–93.5)		0.700
QuestionairesAISN/AN/AN/A2.5
(0.5–3.8)		12.0
(8.0–14.0)		<0.00110.0
(6.3–13.0)		14.0
(10.5–15.0)		0.046
PSQI5.0
(2.5–8.5)		11.0
(7.5–13.0)		0.001N/AN/AN/A10.5
(6.3–12.0)		13.0
(10.0–14.5)		0.090
Sleep latency
(component 2 PSQI)		0.0
(0.0–0.5)		2.0
(1.0–2.0)		<0.001N/AN/AN/A2.0
(1.0–2.0)		2.0
(1.0–2.5)		0.356
Sleep duration
(component 3 PSQI)		1.0
(0.5–1.0)		2.0
(1.0–2.0)		0.014N/AN/AN/A1.0
(1.0–2.0)		2.0
(0.5–2.5)		0.690
Sleep efficiency
(component 4 PSQI)		0.0
(0.0–0.5)		2.0
(1.0–3.0)		<0.001N/AN/AN/A2.0
(1.0–2.8)		2.0
(1.0–2.5)		0.792
Sleep disturbance
(component 5 PSQI)		0.0
(0.0–1.0)		1.5
(0.0–3.0)		0.044N/AN/AN/A1.0
(0.0–2.8)		2.0
(0.5–3.0)		0.385
Use of sleep medication (component 6 PSQI)
[yes (%)/no (%)]		6(100%)/0(0%)18(75%)/6(25%)0.171N/AN/AN/A20(83.3%)/4(16.7%)4(66.7%)/2(33.3%)0.361
Daytime dysfunction
(component 7 PSQI)		0.0
(0.0–2.5)		0.0
(0.0–0.8)		0.327N/AN/AN/A0.0
(0.0–0.0)		1.0
(0.0–2.0)		0.327
Sleep latency
(component 2 PSQI)		1.0
(0.5–3.0)		1.0
(1.0–2.0)		0.973N/AN/AN/A1.0
(1.0–2.0)		2.0
(1.5–3.0)		0.127
Reported time spent lying in bed in PSQI (min)534.0 ± 57.7425.4 ± 99.20.027N/AN/AN/A77.4 ± 15.372.6 ± 17.10.726
Subjective Sleep Efficiency in PSQI (%)90.2 ± 13.873.7 ± 14.40.027N/AN/AN/A441.0 ± 105.2459.0 ± 89.80.541
BDI7.0
(2.0–10.5)		14.0
(8.5–19.5)		0.0139.0
(5.0–9.0)		13.5
(8.0–18.3)		0.033N/AN/AN/A
Protein ConcentrationBDNF evening [ng/mL]6.6
(6.2–8.1)		18.8
(6.1–26.7)		<0.001 *6.6
(6.4–8.1)		17.5
(6.0–26.4)		<0.001 *9.8
(6.3–26.4)		6.1
(4.9–24.9)		0.303
BDNF morning [ng/mL]14.0
(8.0–17.8)		14.4
(6.6–28.0)		0.27713.4
(6.9–17.3)		16.2
(6.6–26.7)		0.22216.2
(8.0–26.7)		6.6
(5.2–14.3)		0.047 **
proBDNF evening [ng/mL]3.1
(2.1–3.8)		9.7
(2.5–28.0)		<0.001 *2.9
(2.0–4.0)		8.6
(2.5–13.9)		<0.001 *4.9
(2.6–13.9)		2.6
(2.0–10.8)		0.388
proBDNF morning [ng/mL]6.0
(3.6–9.2)		5.8
(2.7–12.3)		0.6305.8
(2.7–8.6)		6.1
(2.9–12.0)		0.5047.8 ± 5.13.5 ± 1.70.003 **
AHI—apnea-hypopnea index; AIS—Athens Insomnia Scale; BDI—Beck Depression Inventory; BDNF—brain-derived neurotrophic factor; BMI—body mass index; N/A – not applicable; NREM—non-rapid eye movement sleep; OSA—obstructive sleep apnea, proBDNF—premature brain-derived neurotrophic factor; PSQI—Pittsburgh Sleep Quality Index; REM—rapid eye movement sleep; SpO2—oxygen saturation; TST—total sleep time; * small effect size; ** medium effect size.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Gabryelska, A.; Turkiewicz, S.; Ditmer, M.; Karuga, F.F.; Strzelecki, D.; Białasiewicz, P.; Sochal, M. BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms. J. Clin. Med. 2022, 11, 7135. https://doi.org/10.3390/jcm11237135

AMA Style

Gabryelska A, Turkiewicz S, Ditmer M, Karuga FF, Strzelecki D, Białasiewicz P, Sochal M. BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms. Journal of Clinical Medicine. 2022; 11(23):7135. https://doi.org/10.3390/jcm11237135

Chicago/Turabian Style

Gabryelska, Agata, Szymon Turkiewicz, Marta Ditmer, Filip Franciszek Karuga, Dominik Strzelecki, Piotr Białasiewicz, and Marcin Sochal. 2022. "BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms" Journal of Clinical Medicine 11, no. 23: 7135. https://doi.org/10.3390/jcm11237135

APA Style

Gabryelska, A., Turkiewicz, S., Ditmer, M., Karuga, F. F., Strzelecki, D., Białasiewicz, P., & Sochal, M. (2022). BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms. Journal of Clinical Medicine, 11(23), 7135. https://doi.org/10.3390/jcm11237135

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop